Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 Versus Placebo in Gout Patients

NCT05119686 is registered in ClinicalTrials.gov with Arthrosi Therapeutics as lead sponsor.

NCT NCT05119686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05119686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of AR882 Versus Placebo in Gout Patients
Lead sponsor
Arthrosi Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
November 16, 2021
Completion date
November 17, 2022
Enrollment
140 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, gouty, gout, gout chronic, hyperuricemia